BACKGROUND To investigate the efficacy of neoadjuvant chemotherapy (NCT), neoadjuvant endocrine therapy (NET) and neoadjuvant chemoendocrine therapy (NCET) on the tumour response, including pathological complete response (pCR) rate and overall response rate (ORR), in postmenopausal women with hormone receptor (HR)-positive breast cancer. METHODS Based on a PRISMA-IPD statement, the PubMed, Embase and Cochrane Library databases were used to identify eligible trials published from inception to 7 May 2019. Pooled odds ratio (OR) with 95% confidential interval (CI) was calculated to assess the pCR rate and ORR of tumours among those three treatments via fixed- or random-effect Mantel-Haenszel models in terms of a Heterogeneity Chi2 test with a significant level of p < 0.1. All statistical tests were performed by the software of StataSE, version 12.0. RESULTS The analysed data consisted of 10 eligible clinical trials with 971 unique HR-positive breast cancer patients. The pooled results indicated that the pCR rate of those patients undergoing NET was significantly lower than those undergoing NCT (pooled OR, 0.48; 95% CI, 0.26-0.90), whereas the difference of ORR between both therapies was not statistically significant (pooled OR, 1.05; 95% CI, 0.73-1.52). The combined paradigm of NCET compared with the monotherapy of NET or NCT did not present a significantly improved pCR rate or ORR (pooled OR, 2.61; 95% CI, 0.94-7.25; and 2.25; 95% CI, 0.39-13.05; respectively). CONCLUSION Postmenopausal HR-positive breast cancer patients after NCT may have better tumour response than those after NET, while those undergoing NCET may not manifest the apparently improved clinical efficacies compared to those receiving monotherapy.

中文翻译：

---

接受不同类型新辅助治疗的绝经后激素受体阳性乳腺癌的肿瘤反应：一项荟萃分析。

背景为了研究绝经后女性绝经后女性新辅助化疗（NCT），新辅助内分泌治疗（NET）和新辅助化学内分泌治疗（NCET）对肿瘤反应（包括病理完全反应（pCR）率和总体反应率（ORR））的疗效。激素受体（HR）阳性乳腺癌。方法根据PRISMA-IPD声明，使用PubMed，Embase和Cochrane图书馆数据库鉴定从开始到2019年5月7日发表的合格试验。计算合并机率（OR）和95％机密间隔（CI）来评估通过异质Chi2检验，通过固定或随机效应Mantel-Haenszel模型在这三种治疗方法中，肿瘤的pCR率和ORR的显着水平为p <0.1。所有统计测试均由StataSE版本12的软件执行。0.结果分析的数据由10项符合条件的临床试验组成，这些试验包括971名独特的HR阳性乳腺癌患者。汇总结果表明，接受NET的患者的pCR率显着低于接受NCT的患者（合并OR，0.48； 95％CI，0.26-0.90），而两种疗法之间的ORR差异无统计学意义（合并OR） ，1.05； 95％CI，0.73-1.52）。与NET或NCT的单药治疗相比，NCET的联合治疗范式未显示pCR率或ORR显着改善（合并OR为2.61; 95％CI为0.94-7.25; 2.25; 95％CI为0.39-13.05） 。结论NCT后绝经后HR阳性乳腺癌患者的肿瘤反应可能比NET后更好，